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Abstract
Inverse planning algorithms for dwell time optimisation in interstitial high-dose-rate (HDR) brachyther-
apy may produce solutions with large dwell time variations within catheters, which may result in undesirable
selective high-dose subvolumes. Extending the dwell time optimisation model with a dwell time modula-
tion restriction (DTMR) that limits dwell time differences between neighboring dwell positions has been
suggested to eliminate this problem. DTMRs may additionally reduce the sensitivity for uncertainties in
dwell positions that inevitably result from catheter reconstruction errors and afterloader source positioning
inaccuracies. This study quantifies the reduction of high-dose subvolumes and the robustness against these
uncertainties by applying a DTMR to template-based prostate HDR brachytherapy implants.
Three different DTMRs were consecutively applied to a linear dose-based penalty model (LD) and a
dose-volume based model (LDV), both obtained from literature. The models were solved with DTMR levels
ranging from no restriction to uniform dwell times within catheters in discrete steps. Uncertainties were
simulated on clinical cases using in-house developed software, and dose-volume metrics were calculated in
each simulation. For the assessment of high-dose subvolumes, the dose homogeneity index (DHI) and the
contiguous dose volume histogram were analysed. Robustness was measured by the improvement of the
lowest D90% of the planning target volume (PTV) observed in the simulations.
For (LD), a DTMR yields an increase in DHI of approximately 30% and reduces the size of the largest
high-dose volume by 2 to 5 cc. However, this comes at a cost of a reduction in D90% of the PTV of 10%,
which often implies that it drops below the desired minimum of 100%. For (LDV), none of the DTMRs
were able to improve high-dose volume measures. DTMRs were not capable of improving robustness of PTV
D90% against uncertainty in dwell positions for both models.
This is an author-created, un-copyedited version of an article published in Physics in Medicine and Biology DOI:10.1088/0031-
9155/60/2/537.
1 Introduction
Interstitial high-dose-rate (HDR) brachytherapy with a high activity 192Ir stepping source using remote after-
loading has shown to be an excellent treatment option for localised prostate cancer in any risk category. Its high
tumour control and low toxicity rates result from the precision and control with which this highly conformal
treatment can be delivered (Yamada et al., 2012).
In modern treatment planning systems, automated techniques for anatomy-based inverse treatment planning
enable a fast adjustment of the source dwell time distribution within implanted catheters. The fundament of
these automated techniques is a mathematical optimisation model that uses dose penalty functions for the
planning target volume (PTV) and all relevant organs at risk (OARs) to achieve pre-set dose requirements.
Several optimisation algorithms, like the inverse planning simulated annealing (IPSA, Lessard and Pouliot
2001) and hybrid inverse planning optimisation (HIPO, Karabis et al. 2005) algorithms have been described in
the literature to solve this task.
Often these algorithms produce solutions with large dwell time variations within catheters (Holm et al., 2012).
This may give rise to the following problems related to treatment plan robustness against uncertainties in dose
delivery. Firstly, large dwell times may produce selective high-dose subvolumes around dominant dwell positions.
As stated by Baltas et al. (2009), these high-dose subvolumes should be avoided unless dose inhomogeneities in
the target volume are biologically motivated. Secondly, catheters with large dwell time variations are expected
to yield a heterogeneous dose distribution. Since a longitudinal displacement of the catheter implies that a dwell
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position may shift to the location of its neighbor, heterogeneous dose distributions are expected to be more
susceptible to uncertainties in dwell positions. Such uncertainties can be caused by catheter reconstruction
errors and (mechanical) source positioning inaccuracies of the afterloader as well as inter- and intra-fraction
catheter displacement.
1.1 Clinical procedure and workflow
This study is based on a local clinical procedure for HDR brachytherapy delivered in two fractions of 8.5 Gy with
a one-week interfraction interval. The brachytherapy fractions were a boost to external radiotherapy delivered
in 13 fractions of 2.75 Gy, based on the work by Hoskin et al. (2007). Prior to treatment, the patient was
placed in dorsal lithotomy position, and was not moved until the treatment fraction had been completed. First,
transrectal ultrasound (TRUS) images were acquired using an endocavity biplane transducer (type: 8848, BK
Medical, Herlev, Denmark) with an image resolution of 0.1 mm/pixel at 6 MHz, and relevant tissue structures
were contoured. Second, a so-called pre-plan was made, where the catheter configuration as well as the dwell
times were optimised via inverse planning. For each fraction, a new implant was made using rigid stainless
steel trocar needles (hereafter referred to as ‘catheters’). In the third step, catheters were inserted under TRUS
guidance, using a transperineal template with a hole spacing of 5 mm. Fourth, new TRUS images were acquired,
on which catheter locations were reconstructed and structure delineations were adapted when necessary. Since
we made use of rigid needles, catheter reconstruction was performed by localising two points: the first point is
the location of the catheter at the template, which was known, and the second point is the catheter tip, which
was identified on the TRUS scan. In the fifth phase, a treatment plan was developed based on the delineations
and catheter reconstructions using inverse planning (HDRplus version 3.0, Eckert and Ziegler BEBIG GmbH,
Berlin, Germany). This work only considers the dwell time optimisation in this fifth step, where a fixed catheter
configuration was given. Finally, after plan evaluation and approval the treatment was delivered using a 192Ir
source.
1.2 High-dose subvolumes
Small high-dose subvolumes inevitably occur around each of the dwell positions, where the sizes of the regions
depend on the respective dwell times. When large dwell times occur, the high-dose subvolumes around two neigh-
boring dwell positions may get connected, resulting in a large high-dose subvolume. Without (radio)biological
information about intra-tumour heterogeneity, such large high-dose subvolumes may cause irreversible damage
to the stromal tissue causing necrosis, and hence are considered an undesirable property of a dose distribution.
Therefore, it is reasonable to avoid the formation of such high-dose subvolumes.
The dose-volume characteristics of the largest high-dose subvolume for a range of dose levels expressed as a
percentage of the prescription dose is reflected in the contiguous dose-volume histogram (DVHc). Thomas et al.
(2007) used the DVHc to quantify dose heterogeneity and perform a contiguous volume analysis in post-implant
dosimetry of permanent prostate brachytherapy.
Besides DVHc, which is a local measure as it concerns only a single high-dose volume, we consider the global
dose homogeneity index (DHI), which is calculated as (Wu et al., 1988):
DHI =
V100% − V150%
V100%
,
where Vx% denotes the volume fraction receiving at least x% of the prescribed dose. DHI can be interpreted
as the volume fraction receiving a dose between 100% and 150% of the prescribed dose relative to the volume
receiving at least 100% of the prescribed dose. The higher the DHI, the more uniform is the dose distribution
within the target volume.
While DVHc applies to the largest volume receiving at least a certain dose, interest may also be in the
second or third largest volume. We only take these into account indirectly via the DHI for a dose of 150% of
the prescribed dose. In order to see this, note that 1− DHI = V150%/V100%, which is the total volume of all
regions receiving at least 150% of the prescribed dose as a fraction of the total volume receiving at least the
prescribed dose.
1.3 Uncertainty in dwell locations
A generally acknowledged problem encountered in HDR brachytherapy is the uncertainty in the location of the
dwell positions, resulting in a difference between the intended dose distribution and the one actually delivered
(Kirisits et al., 2014). Here, we identify three causes. The first cause is a catheter positioning error, which occurs
when the catheter is not exactly positioned during implantation as it was planned in the pre-plan (Abolhassani
et al., 2007). We do not consider this type of error here, since we focus on cases where the catheters have already
been inserted. The second cause is a reconstruction error: it is difficult to determine the exact location of the
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catheter tip from TRUS imaging data (Siebert et al., 2009). This uncertainty translates to an uncertainty in the
location of each of the dwell positions within that catheter. The third cause is a source positioning error caused
by mechanical inaccuracies of the remote afterloading system, resulting from the accuracy of the afterloader as
well as uncertainty in the pathlength of the source guide transit tube. The latter may be bent, causing an error
in the distance from the afterloader to the source. These inaccuracies result in all dwell positions within one
catheter to shift in the same direction with the same magnitude.
When the expected locations of the dwell positions differ from the true locations, the delivered dose distri-
bution differs from the expected dose distribution. Treatment plans that are more robust, i.e., for which the
dose distribution is less susceptible to uncertainties, are preferred in clinical practice.
1.4 Dwell time modulation restrictions
In the literature it has been proposed to regularise the dwell time distribution per catheter by adding a dwell
time modulation restriction (DTMR) to the optimisation model (Baltas et al., 2009). This is a constraint that
puts a restriction on the difference between dwell times of adjacent dwell positions. In Gorissen et al. (2013), a
DTMR restricting the relative dwell time difference was used. Van der Laarse and Prins (1994) considered the
sum of squared differences between dwell times of adjacent dwell locations.
DTMRs are available in commercial treatment planning systems, as for example in the real-time intra-
operative planning system Oncentra Prostate (Nucletron B.V., Veenendaal, The Netherlands) that employs
the HIPO (Karabis et al., 2005) and the IPSA algorithm (Lessard and Pouliot, 2001; Alterovitz et al., 2006).
Here, a user-selectable level between 0 and 1 allows for different degrees of dwell time modulation. To the
best of our knowledge, no mathematical definition of the DTMR has been published for these particular dwell-
time optimisation algorithms, and the quantitative interpretation of the various restriction levels hence remains
unclear. Baltas et al. (2009) and Mavroidis et al. (2010) have studied the effects of a DTMR in HIPO, and
stated that including a DTMR results in treatment plans with fewer high-dose subvolumes and lower total dwell
time. Unfortunately, neither of these articles substantiates the statement regarding the reduction in high-dose
subvolumes.
1.5 Aim of the paper
The aim of this study is to quantify the assumed improvement in treatment plan quality caused by DTMRs
in HDR brachytherapy of the prostate. We measure the reduction in high-dose subvolumes caused by three
different DTMRs in existing dose- or dose-volume based inverse treatment planning models and are the first to
do so in a quantitative manner. Furthermore, this study is the first to assess robustness against uncertainties
in dwell locations as a result of these DTMRs. It is our aim to investigate the effect of an increasing DTMR
level, not to consider treatment quality for a single DTMR level.
2 Methods and materials
2.1 Dwell time optimisation models
For our analysis, we used two different dwell time optimisation models. The first model is the linear dose (LD)
model by Alterovitz et al. (2006), which forms the basis for the IPSA algorithm. This model assigns a penalty
to each dose calculation point receiving a dose below the preset lower bound or above the preset upper bound,
where the penalty is linear in the difference between the dose and the corresponding bound. The objective is to
minimise the total penalty. Recently, new optimisation models have been developed that directly optimise dose-
volume histogram (DVH) parameters (Siauw et al., 2011; Gorissen et al., 2013). The second model we use is the
linear dose volume (LDV) model decribed by Gorissen et al. (2013). This model maximises the number of dose
calculation points in the PTV that receive at least the prescribed dose, while restricting the dose received by
the hottest ten percent of the rectum and urethra, denoted by D10%(rectum) and D10%(urethra), respectively.
2.2 Modulation restrictions
Both the (LD) and (LDV) models contain the variable tj , which denotes the dwell time of dwell position j in
seconds. A restriction can be placed on the dwell time gradient of neighboring dwell positions using these dwell
time variables. Gorissen et al. (2013) have introduced DTMR-R:
tj1 ≤ (1 + γ)tj2 ∀j1 ∈ J, ∀j2 ∈ Γ(j1), (1)
where γ denotes the pre-set maximum relative difference between two adjacent dwell positions, j1 and j2 denote
two dwell positions, J denotes the set of dwell positions and Γ(j) denotes the set of all dwell positions adjacent
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to dwell position j. Thus, constraint (1) holds for all dwell positions and all his neighbours. Note that this also
implies the reversed constraint, where the dwell time of dwell position j2 cannot exceed (1 + γ)tj1 .
Instead of restricting the relative differences as in constraint (1) we can restrict the absolute difference
between dwell times of two adjacent dwell positions. We introduce DTMR-A, formulated as:
tj1 − tj2 ≤ θ ∀j1 ∈ J, ∀j2 ∈ Γ(j1), (2)
where θ is the pre-set maximum absolute difference between two adjacent dwell positions. Just as constraint
(1), constraint (2) works two ways.
Note that the behavior of DTMR-R and DTMR-A is very different. For DTMR-A, the allowed dwell time
difference is independent of the dwell times of neighbouring dwell positions. On the other hand, when using
DTMR-R, a larger dwell time allows a larger absolute difference between the dwell times of neighbouring dwell
positions.
Finally, DTMR-Q is introduced as a modification of the quadratic penalty first described by Van der Laarse
and Prins (1994):
1
2
∑
j1∈J
∑
j2∈Γ(j1)
(tj1 − tj2)2 ≤ ρ, (3)
where ρ is some pre-set maximum on the sum of squared differences between dwell times of adjacent dwell
positions.
2.3 Patient data and simulations
In order to investigate the effects of the different DTMRs on the quality of the dose distribution, the three
restrictions were applied to the (LD) and (LDV) dwell time optimisation models.
For the numerical evaluation clinical data from three prostate cancer patients were used, where the rectum
and urethra are the delineated OARs. These three patients cover various prostate sizes: 32, 55 and 48 cc,
respectively. The PTV was defined as the clinical target volume (i.e., the prostate) extended with a 2 mm
margin. The catheter positions used had been chosen by an experienced treatment planner. For patients 1 and
2, 16 catheters were used, and 14 were used for patient 3.
Patient data were obtained from the treatment planning system (HDRplus, version 3.0, Eckert and Ziegler
BEBIG GmbH, Berlin, Germany), comprising the sets of dwell positions, catheter positions and dose calculation
points, the parameters necessary for optimisation, and the dose rate kernel matrix containing the dose rate
contribution from each dwell position to each calculation point. We used the same data as Gorissen et al.
(2013). Dose calculation points had been hexagonally distributed over the delineated structures. The dose
rates were determined according to the TG-43 formalism (Nath et al., 1995), with source specific parameters
according to Granero et al. (2006).
For all three patients different treatment plans were obtained by solving the (LD) and (LDV) models extended
with each DTMR for different values for γ, θ and ρ. In the models extended with DTMR-R, 1+γ ranges from 1
to 4.6 with an incremental step size of 10%, implying that the relative difference between dwell times of adjacent
dwell positions is restricted to be 0 up to 360%. Note that 1+γ = 4.6 is closest to the unrestricted case, and for
1+γ = 1 all dwell times within the same catheter are forced to be equal. In the models extended with DTMR-A,
θ varies from 0 to 5 in steps of 0.05, where θ = 5 corresponds to the unrestricted case. In the models extended
with DTMR-Q, ρ varies from 0 to the value implying free modulation, taking 50 steps. The optimisation models
extended with DTMR-R or DMTR-A were solved using CPLEX 12.2 Optimiser (IBM Corporation, Somers,
USA), which is one of the strongest solvers for linear optimisation problems. For (LD) extended with DTMR-Q
we obtained more accurate results using the MOSEK 6.0 solver (Mosek ApS, Copenhagen, Denmark) due to its
strongly developed interior point method. For model (LDV) we stopped the solver as soon as 95% of the PTV
received at least the prescribed dose, or after 30 minutes (on a computer with an Intel Q8400 processor). The
(LDV) model extended with DTMR-Q could not be solved within reasonable time, and is thus not included in
the analysis.
After the treatment plans had been generated, the actual locations of the catheters were perturbed by
means of simulation, resulting in different locations of the dwell positions. Due to the large number of possible
scenarios, at least 10,000 simulations were calculated per patient. Simulated locations are based on deviations
from the nominal (measured) scenario. The accuracies used for simulation are consistent with values reported in
the literature (Pantelis et al., 2004, page 62). Since an error in locating the catheter tip can be in any direction,
for each simulation, the location of the catheter tip was uniformly sampled from a sphere of 2 mm around the
measured position. Together with the fixed and known location of the catheter at the template, this results
in changes both in the angle between the catheter and the template and in the insertion depth of the catheter
in cranial direction. Consequently, all dwell positions in that catheter were moved with the catheter. A single
longitudinal shift was uniformly sampled on the interval [-1,1] mm, which applies to all dwell positions within
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the catheter simultaneously. Dislocations were sampled for each catheter separately. For each treatment plan
obtained, the resulting objective values and DVH evaluation criteria were calculated for every simulation. In
order to assess whether the models provide good and robust treatment plans, the objective value and the DVH
criteria were compared for different DTMR parameter values by simulation.
2.4 Plan quality indicators
We consider the following performance indicators to assess treatment plan quality. In Table 1 the DVH criteria
are shown, based on the 8.5 Gy per fraction boost according to the local treatment protocol. Here, D90%(PTV)
reflects the minimum dose received by the hottest 90% of the PTV as a fraction of the prescribed dose.
Table 1: Dose-volume criteria, based on the protocol by Hoskin et al. (2007).
PTV Rectum Urethra
D90% ≥ 100% D10% ≤ 7.2 Gy D10% ≤ 10 Gy
V100% ≥ 95% D2cc ≤ 6.7 Gy D0.1cc ≤ 10 Gy
V150% ≤ 55%
V200% ≤ 20%
For the assessment of robustness against uncertainty in catheter positions, the objective value is a useful
indicator. Ideally, a robust model does not deteriorate the objective value, while it improves the worst-case
value in the simulations. Furthermore, it decreases the standard deviation among simulations.
The objective of (LD) is only a surrogate for the actual goal, which is to satisfy the preset DVH criteria as
well as possible (Holm, 2011; Gorissen et al., 2013). Therefore, we also consider the results for D90%(PTV),
where robustness in D90% is more important than robustness in the objective value. For the (LDV) model, we
consider the objective (i.e., V100%) as well as D90% of the PTV.
3 Results
The objective values, DVH metrics and high-dose volume measures resulting from the different treatment plans
applied to the simulations are summarised in graphs. Since the number of graphs is huge, we only present the
graphs for the (LD) model using DTMR-R showing the total penalty, D90%(PTV), DHI ad DVH
c (Figures 1a,
1b, 2a and 2b, respectively). The remaining graphs have been included in appendices of the supplementary
data.
3.1 Interpretation of the figures
In all graphs except for those concerning DVHc, the modulation parameter is shown on the horizontal axis.
The smallest value implies a strong DTMR, while the largest value implies free or almost free modulation.
Consequently, the two extreme observations are the same for all modulation restrictions. For example, it does
not matter whether DTMR-A, DTMR-R or DTMR-Q is used when the best plan is the one with the strongest
DTMR, because for all DTMRs a parameter value exists that forces all dwell times to be equal within the same
catheter. In contrast, a specific DTMR is favourable if the best plan is found for non-extreme DTMR parameter
values, i.e., in the middle of the graph. Note that, since (LDV) could not always be solved to optimality, the
results for the extreme modulation restrictions are not exactly the same.
In the figures displaying the total penalty or dose-volume parameters, the three solid lines represent the
average, the maximum and the minimum value over all simulations, and the dotted curve represents the value
when all locations of the dwell positions are as derived from the imaging data (i.e., nominal value). The grey
area denotes the values within a distance of one standard deviation from the mean.
By way of example, we briefly describe the interpretation of Figure 1b. From this figure we see that for the
strongest modulation restriction, i.e., when 1 + γ = 1, the minimum, mean and maximum D90%(PTV) over all
simulations are approximately 99.9%, 105% and 109%, respectively. This implies that for patient 1 D90%(PTV)
is 99.9% in the worst case scenario. The D90%(PTV) is 106% if the dwell locations are exactly as in the nominal
scenario, which can be concluded from the dotted line representing the nominal value. When the treatment
plan developed with (LD) and DTMR-R with 1+γ = 1 is used, the values for D90%(PTV) that deviate at most
one standard deviation from the mean lie between 104% and 106%.
As opposed to DHI and dose-volume metrics, DVHc is not a single value, but a 2D graph that depends on
the DTMR level. Therefore, a 3D graph was included to show the DVHc as a function of the DTMR levels.
Since we do not consider robustness of DVHc, only the nominal case is shown.
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3.2 Relative dwell time difference restricted in (LD)
The results obtained from (LD) extended with the relative dwell time difference constraint (1) are discussed in
this subsection. First, the results concerning robustness are discussed, followed by high-dose volume measures.
Note that we are not interested in the absolute values of the quality indicators, but merely in the improvements
as a result of applying a DTMR. Hence, we will only consider deviations in parameter values caused by applying
a stronger restriction.
From Figure 1a, it is evident that the range of penalties among the simulations becomes smaller when
the DTMR gets stronger. Furthermore, the penalty for the worst-case scenario becomes smaller. From these
two observations, we conclude that adding a strong DTMR-R to the (LD) model yields solutions with robust
penalty values. However, the results in Figure 1b show that a strong modulation restriction yields a decrease
in the D90%(PTV). For patient 1 this decrease does not result in insufficient target coverage, but for patients
2 and 3 it drops below the minimum desired level of 100% (supplementary data: Figures A5b and A5c). The
standard deviation decreases slightly, but the D90%(PTV) for the worst-case scenario strongly decreases. We
thus conclude that DTMR-R does not yield robustness of the D90% for the PTV, and leads to compromised
target coverage.
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Figure 1: Graphs for patient 1 showing: (a) penalty and (b) D90%(PTV) generated by (LD) extended with
DTMR-R. The solid lines represent the minimum, mean and maximum values, and the dotted line is the pre-plan
value. The grey area denotes values at most one standard deviation from the mean.
The results for the remaining DVH parameters for the PTV as well as those for the OARs can be found
in Appendix A of the supplementary data. From these figures, we conclude that for all patients, a strong
restriction on the relative dwell time differences results in a large reduction of V100%, and a slight reduction of
V150% and V200%. Also rectum D2cc and D10% slightly decrease, whereas urethra D0.1cc and D10% stay at the
same level.
High-dose subvolumes are the second feature under consideration. Figure 2a shows that for patient 1, DHI
is optimal for the weakest as well as the strongest DTMR. For patients 2 and 3, the highest DHI is obtained
for a strong modulation restriction (supplementary data: Figures A2b and A2c). From Figure 2b, one can see
that the strongest DTMR yields the best DVHc for patient 1. The same conclusion can be drawn for patients
2 and 3 (supplementary data: Figures A3b and A3c). Note that this is a trivial consequence from the decrease
in D90%.
From the above we conclude that including DMTR-R in (LD) can result in undesirable treatment plans
when considering the D90% for the PTV. Furthermore, it does result in robustness of the penalty, but not in
robustness of the D90%. A strong DMTR-R slightly improves high-dose subvolumes according to the DHI and
DVHc and slightly reduces the dose to the rectum, but this is a trivial consequence of an undesirably low D90%.
3.3 General results
The results for the (LD) model extended with DTMR-A and DTMR-Q are similar to the results for the (LD)
model extended with DTMR-R and do not need a separate discussion. The (LDV) curves do show a large
variation, of which the main cause is that we did not solve these models to optimality. Therefore, we should
consider the trend, rather than the individual values. For the (LDV) model extended with DTMR-R and DTMR-
A the DTMRs did not provide treatment plans with improved high-dose volume indicator values, and sometimes
even worse high-dose volume indicator values were found. Furthermore, for some patients our DTMRs yield
lower values for the D90% of the PTV.
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Figure 2: Graphs for patient 1 showing: high-dose volume performance indicators (a) DHI and (b) DVHc
generated by (LD) extended with DTMR-R. The solid lines in graph (a) represent the minimum, mean and
maximum values, and the dotted line is the pre-plan value. The grey area denotes values at most one standard
deviation from the mean.
4 Discussion
For prostate HDR brachytherapy dose distributions, the effects of DTMRs were assessed in several other papers
as well. Baltas et al. (2009) and Mavroidis et al. (2010) used data from 12 clinical implants in combination
with the HIPO algorithm. The dosimetric quality of these implants was assessed for plans optimised with and
without DTMR, such that DVH parameters of their protocol were completely fulfilled. This resulted in a slight
reduction (<2%) in DVHs for the prostate and a more pronounced sparing of the OARs, especially urethra and
bladder. However, our work does not support this conclusion. We observed a decrease in target coverage of
approximately 10% when using a DTMR.
Baltas et al. (2009) and Mavroidis et al. (2010) have found a lower mean dwell time per implant and a mean
total dwell time reduction of 1.4%, that both were proven to be statistically significant. In our opinion, part of
the reduction in total dwell time for the plan with DTMR can be explained by the average observed reduction
in D90% for the PTV. Using (LD), we observed that each of the three DTMRs resulted in a mean total dwell
time reduction of 3−5%. For DTMR-R and DTMR-A the total dwell time decreased gradually as the restriction
became stronger, whereas for DTMR-Q the reduction takes place only when dwell times are forced to be equal
within the same catheter. For (LDV) there were no differences in mean total dwell time between the plans with
and without DTMR.
High-dose volume parameters do not show improvements as a result of the DTMR for the (LDV) model. For
the (LD) model, the DTMR can improve high-dose volume measures only while compromising target coverage.
A trade-off between these two goals thus needs to be made. For patient 1, the decrease in coverage is not
problematic, but for patients 2 and 3 it drops below the desired minimum. The effects of a DTMR do not only
differ among patients, but also among models, which indicates that the different effects may not depend on the
implant quality and patient characteristics.
Holm (2013) suggested another method to improve the dose homogeneity by incorporating the DHI into the
objective function. When comparing their optimisation model to the original linear penalty model by Alterovitz
et al. (2006), they found no significant difference in treatment plan quality when comparing the DHI. Thus, an
effective optimisation method to improve dose homogeneity in prostate HDR brachytherapy still needs to be
established.
For the assessment of a DTMR’s capabilities to improve robustness against uncertainties in dwell locations,
we took catheter reconstruction errors and the source positioning inaccuracy of the afterloader into account.
The simulated errors are of the same order of magnitude as those reported in literature (Siebert et al., 2009;
Pantelis et al., 2004; Peikari et al., 2012), though we neglected the difference in error magnitude between the
various directions. The magnitude of variation in D90% and V100% for the PTV we found as a result of these
errors corresponds to values reported by Kirisits et al. (2014), though Pantelis et al. (2004) found variabilities of
approximately half the magnitude of the errors we found. This difference may arise from the fact that Pantelis
et al. (2004) derived DVH metrics from the average dose to a calculation point, and as such ignored the risks
occurring in individual scenarios.
The results of the current study show that the DTMR is not suitable for the development of robust treatment
plans. Therefore, these uncertainties need to be included in the optimisation model in a different way. Examples
of methods to take uncertainties into account are robust optimisation (Ben-Tal et al., 2009) and stochastic
programming (Kall and Wallace, 1994). Future research is required to assess the potential benefit for robust
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brachytherapy treatment planning.
Additional uncertainties arise in various stages of the treatment process. Examples are delineation variabil-
ities, catheter deflection, organ deformations, dislocation of the implant between fractions (Kirisits et al., 2014)
and transit dose contribution (Fonseca et al., 2014). The effects of those uncertainties as well as methods to
overcome them are interesting topics for future research, especially for different catheter configurations.
Our study has some limitations. Firstly, the use of rigid needles allowed us to determine catheter locations
by localising two points on each catheter. However, flexible catheters are used in clinics where the implant
remains in situ between fractions. When performing a similar study with flexible catheters, indicating two
points on a catheter is insufficient for identification of the complete catheter location, and uncertainties should
be simulated in a different way.
Secondly, the number of patients is small. This allowed us to perform the highly detailed study that was
necessary to address the effects of a DTMR on high-dose subvolumes and robustness. The results for all three
patients were negative, and DTMRs sometimes even showed to result in deterioration of the plan quality.
Including more patients in this study would not have changed the negative results for these three patients.
Therefore, despite the small number of patients, we conclude that DTMRs do not in general improve treatment
plan quality, as they were expected to. This does not imply that a DTMR has negative effects for every patient:
patients for whom a DTMR has positive effects may exist. Investigating the effects of a DTMR for each patient
prior to treatment would take up too much time. However, we do recommend other institutions to perform a
similar study in order to quantitatively assess the influence of a DTMR on robustness, homogeneity and DVH
parameters.
5 Conclusion
Although robustness in the penalty of the (LD) model is obtained from all three DTMRs, no improvement in
robustness of the D90%(PTV) was obtained by applying any of the three DTMRs for the (LD) and (LDV) mod-
els. Furthermore, these DTMRs do not reduce the high-dose subvolumes without simultaneously deteriorating
D90%(PTV). Finally, no significant sparing of the OARs is achieved, unless the dose delivered at the PTV is
decreased as well.
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